Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug

October 20, 2022 - 3 minutes
Photo/Shutterstock

Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients.

It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). 

Tiziana plans on filing the IND for Alzheimer’s disease by the third quarter of 2023 upon the completion of requested toxicology studies, then starting its phase 1 program by the end of 2023.

Tiziana is a U.S. biotechnology company developing immunomodulation therapies via novel routes of drug delivery.

Multiple indications

“I am thrilled to see the company advancing foralumab into another promising central nervous system (CNS) -related therapeutic area with high unmet need,” said Gabriele Cerrone, executive chairman and interim CEO of Tiziana Life Sciences. 

“Intranasal foralumab’s unique action on regulatory T-cells should allow us to study multiple CNS inflammatory pathology indications for this unique drug, including in multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).”

Content continues below

Related Content

“We have spent years studying intranasal anti-CD3, or foralumab, in inflammatory CNS-related disease models in animals,” said Howard L. Weiner, co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital. 

“We look forward to evaluating intranasal foralumab in patients with early symptomatic Alzheimer’s disease, where we believe its locally acting anti-inflammatory mechanism of action will be relevant.”

“Tiziana strongly believes that many inflammatory CNS disease pathologies could improve with intranasally administered foralumab and as such, we hope to study additional neurological disease states over time,” said Matthew Davis, chief scientific officer and chief medical officer of Tiziana Life Sciences.

About foralumab

Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, has shown reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn’s disease. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells (Tregs), thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. 

Once a day treatment for 10 consecutive days with intranasal foralumab was both well tolerated and produced clinical responses in COVID-19 patients. Based on these studies, the intranasal and oral administration of foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs.

You might also be interested in the following: